6/13
04:04 pm
nktx
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors [Yahoo! Finance]
Medium
Report
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors [Yahoo! Finance]
6/13
04:01 pm
nktx
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
Medium
Report
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
5/25
02:47 am
nktx
Nkarta: Finally An Attractive Valuation [Seeking Alpha]
Low
Report
Nkarta: Finally An Attractive Valuation [Seeking Alpha]
5/23
11:53 am
nktx
Nkarta: A Look Into Q1 Results And Upcoming Catalysts [Seeking Alpha]
Low
Report
Nkarta: A Look Into Q1 Results And Upcoming Catalysts [Seeking Alpha]
5/15
04:20 pm
nktx
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors [Yahoo! Finance]
Low
Report
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors [Yahoo! Finance]
5/13
02:05 pm
nktx
Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at Needham & Company LLC from $15.00 to $13.00. They now have a "buy" rating on the stock.
Low
Report
Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at Needham & Company LLC from $15.00 to $13.00. They now have a "buy" rating on the stock.
5/11
08:37 am
nktx
Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
High
Report
Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
5/10
03:43 pm
nktx
Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $16.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $16.00 to $15.00. They now have a "buy" rating on the stock.
5/9
04:12 pm
nktx
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]
Low
Report
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]
5/9
04:01 pm
nktx
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
Low
Report
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
5/1
07:45 am
nktx
CD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity Insight [Yahoo! Finance]
High
Report
CD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity Insight [Yahoo! Finance]
4/27
10:39 am
nktx
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead [Seeking Alpha]
Medium
Report
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead [Seeking Alpha]
4/10
08:05 am
nktx
Nkarta, Inc. (NASDAQ: NKTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Medium
Report
Nkarta, Inc. (NASDAQ: NKTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
4/8
12:55 pm
nktx
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
Low
Report
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
4/5
05:44 pm
nktx
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
Medium
Report
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
4/5
03:35 pm
nktx
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
Low
Report
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
4/3
04:02 pm
nktx
Nkarta to Participate in Upcoming Investor Conferences
Low
Report
Nkarta to Participate in Upcoming Investor Conferences
3/26
08:12 am
nktx
Nkarta, Inc. (NASDAQ: NKTX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $15.00 to $16.00. They now have a "buy" rating on the stock.
Medium
Report
Nkarta, Inc. (NASDAQ: NKTX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $15.00 to $16.00. They now have a "buy" rating on the stock.
3/25
04:08 pm
nktx
Nkarta: NK Cell Therapy Advancement On Two Fronts [Seeking Alpha]
Medium
Report
Nkarta: NK Cell Therapy Advancement On Two Fronts [Seeking Alpha]
3/25
10:06 am
nktx
Nkarta, Nuvation Bio, Canopy Growth among healthcare movers Mar. 25, 2024 10:00 AM ET By: Tiyashi Datta , SA News Editor [Seeking Alpha]
Medium
Report
Nkarta, Nuvation Bio, Canopy Growth among healthcare movers Mar. 25, 2024 10:00 AM ET By: Tiyashi Datta , SA News Editor [Seeking Alpha]
3/25
06:36 am
nktx
Nkarta Announces Pricing of $240 Million Underwritten Offering [Yahoo! Finance]
Low
Report
Nkarta Announces Pricing of $240 Million Underwritten Offering [Yahoo! Finance]
3/25
06:30 am
nktx
Nkarta Announces Pricing of $240 Million Underwritten Offering
Medium
Report
Nkarta Announces Pricing of $240 Million Underwritten Offering
3/22
11:20 am
nktx
Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at Mizuho from $31.00 to $25.00. They now have a "buy" rating on the stock.
High
Report
Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at Mizuho from $31.00 to $25.00. They now have a "buy" rating on the stock.
3/22
10:03 am
nktx
Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers [Seeking Alpha]
High
Report
Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers [Seeking Alpha]
3/22
08:07 am
nktx
Nkarta, Inc. (NASDAQ: NKTX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $16.00 price target on the stock, up previously from $13.00.
High
Report
Nkarta, Inc. (NASDAQ: NKTX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $16.00 price target on the stock, up previously from $13.00.